-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點摘要如下: 2026財年第三季業績喜憂參半。營收為102.4億美元(年增123%),低於市場普遍預期的124.5億美元;但非GAAP每股收益為0.84美元,輕鬆超過預期的0.62美元。毛利率從第二季創紀錄的6.3%大幅回升至9.9%(年增30個基點,季增370個基點)。這些喜憂參半的業績可能會令投資人猶豫,尤其是考慮到銷售額未達預期,以及前高階主管違反出口管制規定後持續存在的信譽風險,我們認為這些都引發了人們的擔憂。該公司第四季業績指引預計營收為110億至125億美元(中位數為117.5億美元,高於市場預期的113.1億美元),非GAAP每股收益約為0.72美元,高於市場普遍預期的0.56美元。我們對公司緊張的流動性狀況感到擔憂,現金從40.9億美元降至12.9億美元,而債務從49億美元增至88億美元,主要原因是66億美元的經營現金流出(高於預期的19億美元),其中大部分來自100億美元的應付帳款支付。我們預計,由於出口管制罰款和營運資金需求,Blackwell平台產能擴張所需的庫存增加將進一步加劇流動性壓力。
Related Articles
Simcere Pharmaceutical Receives Chinese Regulatory Approval to Begin Trials of Tumor Drug
Simcere Pharmaceutical (HKG:2096) received Chinese regulatory approval to begin clinical trials of SIM0613, according to a Hong Kong bourse filing Wednesday.The injection is intended to treat advanced solid tumors and is licensed to Ipsen Pharma in regions outside Greater China.
Meitu Records 30% Rise in Paying Subscribers
Meitu (HKG:1357) said the number of paying subscribers using its platform grew 30% year on year to 17.90 million as of end March, according to a Hong Kong bourse filing Wednesday.Paying subscribers for the company's productivity tools grew 53% to 2.34 million, while leisure app subscribers increased 27% to 15.56 million, the firm said.The company's core revenue grew 34.3% year on year to 852 million yuan, while other businesses remained "stable overall."The company's annual recurring revenue for AI-driven productivity apps stood at 580 million yuan as of March, a 56% increase from a year earlier.
Yidu Tech Unit Wins SG$2.3 Million Singapore Healthcare Project
Yidu Tech (HKG:2158) said its subsidiary EVYD Research Private Limited won a contract from Singapore Health Services for the implementation and support of Dr Buddy, according to a Wednesday Hong Kong bourse filing.The total project amount is about SG$2.3 million.